



Updated Monthly

October 4, 2023

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





TABLE OF CONTENTS

New Opportunities

Bioengineering	2
Biomedical Research.....	2
Cancer	3
Cardiovascular and Pulmonary Health.....	4
Cognitive and Brain Health.....	4
Combat Casualty Care.....	4
Complementary and Integrative Health	5
Dental and Craniofacial Research	5
Endocrine and Metabolic Diseases	6
Exposome Research	6
Genomics	6
Health IT & Data	6
HIV/AIDS	8
Immunology & Infectious Disease	9
Maternal and Pediatric Health	9
Medical Countermeasures.....	10
Mental Health.....	10

GBG Report

Updated Monthly

October 4, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

Musculoskeletal Health	10
Regulatory Science	10
Small Business Development	11
Substance Use Disorder	11
Telemedicine	12

Recurring Opportunities

Advanced Research Projects Agency for Health	13
Air Force	13
Army.....	14
BARDA	15
DARPA	16
Defense Threat Reduction Agency	16
Department of Energy	17
National Science Foundation	17
Navy	17
GBG Acronyms	19



October 20, 2023 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EST (FREE and open to all) then from 10:30-11am EST (premium service and private consultation for G2G and GBG customers).

Registration now open: [BARDA Industry Day](#), November 13-14, 2023, at the Grand Hyatt Washington and Virtual. G2G will be there!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOENGINEERING (1)		
1.	ARPA-H Resilient Extended Automatic Cell Therapies (REACT) (ARPA-H) ARPA-H-SN-23-05	REACT aims to overcome the problems surrounding medication non-adherence by creating two different—but related—bioelectronic devices capable of treating chronic conditions remotely. These devices will be implanted in patients during minor outpatient surgery and will interface with a simple software platform or app that allows users to track their condition directly. Proposers' Day is 11/16/23. The BAA is forthcoming. https://sam.gov/opp/00a458a1a252448aac9a5145bbc47c5a/view	Dependent upon proposal and award mechanism	Register for Proposers' Day by 11/6/23
		BIOMEDICAL RESEARCH (8)		
2.	2024 Human Exploration Research Opportunities (HERO) Overview (NASA) 80JSC024NA001 80JSC024NA001-FLAGSHIP 80JSC024NA001-OMNIBUS 80JSC024NA001-NSCOR	The research will fall into one or more categories corresponding to HRP’s five Elements: Space Radiation, Human Health Countermeasures, Exploration Medical Capability, Human Factors and Behavioral Performance, and Research Operations and Integration. This NRA covers all aspects of research to provide human health and performance countermeasures, knowledge, technologies, and tools to enable safe, reliable, and productive human space exploration. Due dates are staggered; Appendices will open through 9/30/24. https://www.grants.gov/web/grants/view-opportunity.html?oppId=350442 https://www.grants.gov/web/grants/view-opportunity.html?oppId=350443 https://www.grants.gov/web/grants/view-opportunity.html?oppId=350444 https://www.grants.gov/web/grants/view-opportunity.html?oppId=350447	Up to \$1.2 million per year, for up to 5 years Dependent upon proposal and award mechanism	Proposal: 11/1/23 (Appendices A-C)
3.	NOSI: Quantum Sensing in Biomedical Applications (SBIR/STTR) (NIH/NEI/NCATS/NCI) NOT-EY-23-009	This NOSI encourages SBCs to develop commercializable tools, resources, and approaches that harness new quantum sensing approaches to solve biomedical research questions with application in areas of preventing, monitoring and diagnosing disease. https://grants.nih.gov/grants/guide/notice-files/NOT-EY-23-009.html	Up to \$295,924 (Phase I)	Multiple deadlines; NOSI open through 9/6/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
4.	Pre-Announcement: Complement-Animal Research in Experimentation (Complement-ARIE) Challenge (NIH Common Fund) NOT-RM-23-025	The Complement-ARIE Challenge seeks to propel the development and refinement of human-centric New Approach Methodologies (NAMs), by developing approaches that complement or replace animal models. Solutions must include next-generation innovation in NAMs for complex in vitro human-derived cell- or tissue-based models, in silico multi-scale systems, in chemico approaches to emulate human biology, and/or integrated NAMs with associated Findable, Accessible, Interoperable, and Reusable (FAIR) datasets and AI-engines. Solutions must demonstrate substantial advancement from the current state-of-the art models and technologies. https://grants.nih.gov/grants/guide/notice-files/NOT-RM-23-025.html	Up to \$50,000	Estimated post date: 11/7/23 Estimated proposal date: 1/11/24
		CANCER (5)		
5.	Cancer Research Education Grants Program (R25 Clinical Trial Not Allowed) (NIH/NCI) PAR-23-276 PAR-23-277 PAR-23-278	The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. These NOFOs support creative educational activities with a primary focus on Courses for Skills Development; Research Experiences; or Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients. https://grants.nih.gov/grants/guide/pa-files/PAR-23-276.html https://grants.nih.gov/grants/guide/pa-files/PAR-23-277.html https://grants.nih.gov/grants/guide/pa-files/PAR-23-278.html	Up to \$300,000 per year, for up to 5 years (Skills and Research) Up to \$150,000 per year, for up to 2 years (Curriculum)	Proposal: 1/25/24
6.	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) (NIH/NCI/NIDCR) PAR-23-284	The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. https://grants.nih.gov/grants/guide/pa-files/PAR-23-284.html	Up to \$1.4 million per year, for up to 5 years	Letter of intent: 12/25/23 Proposal: 1/25/24
7.	Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 CT Optional) (NIH/NCI/SGMRO) PAR-23-292	This NOFO is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. https://grants.nih.gov/grants/guide/pa-files/PAR-23-292.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/5/24 Proposal: 2/5/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH (1)		
8.	NOSI: Advancing Rheumatic Heart Disease Research (R01) (NIH/NHLBI/NIAD) NOT-HL-23-106	This NOSI seeks to advance Rheumatic Heart Disease (RHD) research. There is a critical need to reduce RHD burden within low- and middle-income countries and low-resource settings in high-income countries. The NOSI calls for research proposals across the translational science spectrum within endemic settings to improve health outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-106.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/27
		COGNITIVE AND BRAIN HEALTH (2)		
9.	Pre-Announcement: Microphysiological Systems to Advance Precision Medicine for AD/ADRD Treatment and Prevention (U54 Clinical Trial Not Allowed) (NIH/NIA) NOT-AG-23-059	The overarching objective of this initiative is to create AD/ADRD MPS Translational Centers focused on establishing an infrastructure to develop standardized and deeply phenotyped 2D and 3D MPS models, establishing the translational validity of these MPS models to recapitulate the molecular and network perturbations identified in AD/ADRD, and ensuring rapid and broad distribution of the MPS models, data, and analytical methods for use in basic research and therapy development. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-059.html	Up to \$2.5 million per year	Estimated post date: 10/20/23 Estimated proposal date: 2/15/24
10.	BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) (NIH) RFA-EY-23-001	This NOFO seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation. https://grants.nih.gov/grants/guide/rfa-files/RFA-EY-23-001.html	Up to \$400,000, for up to 3 years	Proposal: 6/18/24
		COMBAT CASUALTY CARE (1)		
11.	Blood and Blood Products State of the Technology Meeting (MTEC) 23-12-Blood	The purpose of this meeting is to inform the US Government and the greater scientific community of innovative research for blood and blood products, in support of current and future military and civilian blood needs for future large scale combat operations, as well as domestic mass casualty and disaster response. Additionally, the meeting will assist the US Government in identifying capability gaps and prioritizing efforts toward blood product development within DoD and across the inter-agency enterprise. The meeting will give an opportunity for a dynamic exchange of ideas among all participants and provide support to identify and overcome challenges. https://mtec-sc.org/wp-content/uploads/2023/09/MTEC-23-12-Blood-RPI.pdf	N/A	Project information paper: 10/23/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMPLEMENTARY AND INTEGRATIVE HEALTH (9)		
12.	Pre-Announcement: Feasibility Clinical Trials of Mind and Body Interventions; Clinical Coordinating Center, and Data Coordinating Center (R34/R01/UG3/UH3/U24 Clinical Trial Required) (NIH/NCCIH) NOT-AT-24-015 (R34) NOT-AT-24-016 (R01) NOT-AT-24-017 (UG3/UH3) NOT-AT-24-018 (U24)	These NOFOs support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs for conditions that have been identified by NCCIH as high priority research topics, as well as Clinical Coordinating Centers and a collaborating Data Coordinating Center. DCC and CCC applications must be submitted simultaneously. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-015.html (R34) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-016.html (R01) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-017.html (UG3/UH3) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-018.html (U24)	Up to \$450,000 (R34) Up to \$350,000 per year (R01) Dependent upon proposal (UG3/UH3)/ (U24)	Estimated post date: 12/4/23 Estimated proposal date: 2/5/24
13.	Pre-Announcement: NCCIH Natural Product Clinical Trials, Clinical Coordinating Center, and Data Coordinating Center (R01/R33/UG3/UH3/R61/R33/U24 Clinical Trial Required) (NIH/NCCIH) NOT-AT-24-019 (R01) NOT-AT-24-020 (R33) NOT-AT-24-021 (UG3/UH3) NOT-AT-24-022 (R61/R33) NOT-AT-24-023 (U24)	These NOFOs will encourage applications for early and mid-phase investigator-initiated clinical trials of natural products, as well as a Clinical Coordinating Center and Data Coordinating Center. DCC and CCC applications must be submitted simultaneously. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-019.html (R01) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-020.html (R33) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-021.html (UG3/UH3) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-022.html (R61/R33) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-023.html (U24)	Up to \$350,000 per year (R01) Up to \$1.05 million (R33) Dependent upon proposal (UG3/UH3) Up to \$350,000 per year (R61/R33) Dependent upon proposal (U24)	Estimated post date: 12/4/23 Estimated proposal date: 2/5/24
		DENTAL AND CRANIOFACIAL RESEARCH (1)		
14.	NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed) (NIH/NIDCR) RFA-DE-24-006	The overall goal of this initiative is to provide sustained and flexible support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, to conduct exceptionally innovative research with extraordinary potential for improving dental, oral, and craniofacial health. https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-24-006.html	Up to \$650,000 per year, for up to 8 years	Letter of intent: 12/26/23 Proposal: 1/26/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE AND METABOLIC DISEASES (2)		
15.	Continuation of the Childhood Liver Disease Research Network (ChiLDRen) Clinical Centers (U01 Clinical Trial Required) and Scientific and Data Coordinating Center (U24 CT Optional) (NIH/NIDDK) RFA-DK-23-017 (U01) RFA-DK-23-018 (U24)	These NOFOs continue the support of the Childhood Liver Disease Research Network (ChiLDRen) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDRen will continue clinical and expand translational research that may include translational science coordination center(s) focused on supporting research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; and primary sclerosing cholangitis (PSC). https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-017.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-018.html (U24)	Dependent upon proposal, for up to 5 years	Proposal: 11/8/23
		EXPOSOME RESEARCH (1)		
16.	Center for Exposome Research Coordination to Accelerate Precision Environmental Health (U24 Clinical Trial Not Allowed) (NIH) RFA-ES-23-010	This NOFO solicits applications for establishing a Center for Exposome Research Coordination (CERC) that will serve the broad biomedical research community by coordinating and advancing exposome research to accelerate precision environmental health. The CERC will engage existing and ongoing exposome initiatives around the globe to promote methodological advancement and best practices, provide training and education, and foster national and international collaborations. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-010.html	Up to \$1.55 million per year, for up to 5 years	Letter of intent: 10/30/23 Proposal: 11/30/23
		GENOMICS (2)		
17.	Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21/R01 Clinical Trial Not Allowed) (NIH/NHGRI) PAR-23-301 (R21) PAR-23-302 (R01)	These NOFOs support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences. https://grants.nih.gov/grants/guide/pa-files/PA-23-301.html (R21) https://grants.nih.gov/grants/guide/pa-files/PA-23-302.html (R01)	Up to \$275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Proposal: 2/16/24 (R21) Proposal: 2/5/24 (R01)
		HEALTH IT & DATA (32)		
18.	ARPA-H Biomedical Data Fabric (BDF) Toolbox (ARPA-H) ARPA-H-SN-23-04	The ARPA-H BDF Toolbox project will create the software foundations that make it far easier and faster to integrate these disparate data sources in a meaningful way and make the data available to a broad set of R&D end users to accelerate the development of novel health technologies to improve health outcomes for all Americans. https://sam.gov/opp/58966595c2b6492280d40feba09b1810/view	TBD	Abstract: 10/6/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA		
19.	NOSI: Advancing Data Science Research in HIV: Responding to a Dynamic, Complex, and Evolving HIV Epidemic with Artificial Intelligence/Machine Learning (NIH/NIMH) NOT-MH-23-350	This NOSI seeks to advance data science research in HIV by encouraging the generation of cutting-edge synthetic datasets, artificial intelligence, and machine learning approaches to expand our capacity to address the dynamic, complex, and evolving HIV epidemic. Team science approaches where the strength and expertise of multiple individuals across data and computational sciences, biostatistics, behavioral and social sciences, computer science, and HIV prevention and care, among others, is strongly encouraged. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-350.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/27
20.	Computationally-Defined Behaviors in Psychiatry and Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R21/R01 Clinical Trial Optional) (NIH/NIMH) PAR-23-305 (R21) PAR-23-307 (R01)	These NOFOs solicit applications for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function; and applications for research projects that will use computational approaches to test the validity of dimensional constructs in the NIMH Research Domain Criteria (RDoC) matrix. https://grants.nih.gov/grants/guide/pa-files/PA-23-305.html (R21) https://grants.nih.gov/grants/guide/pa-files/PA-23-307.html (R01)	Up to \$275,000, for up to 2 years (R21) Up to \$500,000 per year, for up to 5 years (R01)	Proposal: 11/1/23
21.	Computational Models of Influenza Immunity (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-056	This program will employ computational modeling and immunologic studies to advance our understanding of the requirements for improving anti-influenza immunity, including inducing broad immune protection and enhancing immune durability. This program will help inform design of universal or improved seasonal flu vaccines. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-056.html	Up to \$750,000 per year, for up to 5 years	Letter of intent: 12/26/23 Proposal: 1/26/24
22.	Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-25-016 (R01) RFA-DA-25-017 (R21)	These NOFOs support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-016.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-017.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 7/13/24 Proposal: 8/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS (8)		
23.	Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21/R01 Clinical Trial Not Allowed) (NIH) PAR-23-296 (R21) PAR-23-297 (R01)	These NOFOs aim to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the ultimate goal of achieving sustained treatment-free remission. https://grants.nih.gov/grants/guide/pa-files/PA-23-296.html (R21) https://grants.nih.gov/grants/guide/pa-files/PA-23-297.html (R01)	Up to \$275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Proposal: 1/7/24
24.	Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Clinical Trials Optional/BESH) Required) (NIH/NIDA) RFA-DA-24-005 RFA-DA-24-006	These NOFOs solicit applications for research aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on substance use disorders (SUDs) and co-occurring psychiatric disorders in people living with HIV (PLWH). https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-005.html https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-006.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 1/15/24 Proposal: 2/15/24
25.	Cohort Studies of HIV/AIDS and Substance Use (U01 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-25-003	This program is a multidisciplinary platform to support basic, epidemiologic, and clinical research on HIV and HIV-associated co-morbidities and co-infections among populations with SUDs and to address research questions at the individual and population level. This NOFO supports the continuation of NIDA's HIV Cohorts Program, encouraging existing and new sites to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance use in alignment with NIH-HIV research priorities in order to inform policy or practice. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-003.html	Dependent upon proposal, for up to 5 years	Letter of intent: 7/16/24 Proposal: 8/16/24
26.	Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01/R21/R34 Clinical Trial Optional) (NIH) RFA-MH-24-330 (R01) RFA-MH-24-331 (R21) RFA-MH-24-332 (R34)	These NOFOs invite applications to understand factors that impact uptake and adherent and persistent use of biomedical HIV prevention options, to inform and advance approaches to support choice and use among these options, and to understand and advance equitable delivery of biomedical HIV prevention options for cisgender and transgender women in settings where multiple prevention options are available. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-330.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-331.html (R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-332.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 10/22/23 Proposal: 11/22/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (5)		
27.	Fc-Dependent Mechanisms of Antibody-Mediated Killing (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-054	This NOFO supports basic research that will elucidate mechanisms of Fc-mediated antibody functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-054.html	Up to \$300,000 per year, for up to 3 years	Letter of intent: 12/26/23 Proposal: 1/26/24
28.	NIH Common Fund Human Virome Program (NIH Common Fund) RFA-RM-23-016 (U24) RFA-RM-23-017 (U01) RFA-RM-23-018 (U01) RFA-RM-23-019 (U54)	The NIH Common Fund HVP's overall goal is to establish a research consortium to extensively characterize the human virome and create tools, models, methods that will enable in-depth study of its variation in relation to host factors and its influence on health and disease. These NOFOs will support tool and technology development, HVP Functional Interaction Studies, the HVP Consortium Organization and Data Collaboration Center (CODCC), and Virome Characterization Centers (VCCs). https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-016.html (U24) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-017.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-018.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-019.html (U54)	Up to \$1.875 million per year, for up to 5 years (U24) Up to \$750,000 per year, for up to 5 years (U01-017) Up to \$350,000 per year, for up to 4 years (U01-018) Dependent upon proposal, for up to 5 years (U54)	Letter of intent: 10/29/23 Proposal: 11/29/23 (U24) Letter of intent: 10/15/23 Proposal: 11/15/23 (U01-017) Letter of intent: 10/14/23 Proposal: 11/14/23 (U01-018) Letter of intent: 10/17/23 Proposal: 11/17/23 (U54)
		MATERNAL AND PEDIATRIC HEALTH (33)		
29.	RADx® Tech Fetal Monitoring Challenge (NIH/NIBIB/NICHD) NOT-EB-23-017	This Challenge aims to accelerate the development of diagnostic and monitoring technologies to reduce the risk of fetal morbidity and mortality and thus improve fetal and neonatal health outcomes. Successful technologies developed in this Challenge will directly measure one or more parameters of fetal health status during the late antepartum and/or intrapartum periods of pregnancy. https://www.challenge.gov/?challenge=radx-tech-fetal-monitoring	\$2 million in total prizes	Proposal: 11/17/23
30.	NOSI: The Road to Prevention of Stillbirth (NIH) NOT-HD-23-021	This NOSI aims to support transdisciplinary research to elucidate the genotypic, phenotypic, and environmental underpinnings of stillbirth and to identify potential targets for intervention and prevention. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-23-021.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/17/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES (1)		
31.	Pre-Announcement: CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed) (NIH/NINDS) NOT-NS-24-008	This NOFO will solicit applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-008.html	Up to \$300,000 per year, for up to 3 years	Estimated post date: 2/29/24 Estimated proposal date: 5/30/24
		MENTAL HEALTH (2)		
32.	Pre-Announcement: Early Psychosis Intervention Network (EPINET): Learning Health Care Research to Improve Mental Health Services and Outcomes (P01 Clinical Trial Optional) and Data Coordinating Center (U24 CT Not Allowed) (NIH/NIMH) NOT-MH-23-295 (P01) NOT-MH-23-296 (U24)	These NOFOs will solicit applications from scientific hubs to support learning health care research in clinics offering evidence-based Coordinated Specialty Care (CSC) to persons in the early stages of psychotic illness. Each scientific hub will link multiple early psychosis service programs through (1) the EPINET Core Assessment Battery (CAB) of early psychosis clinical features, CSC services, and treatment outcomes; (2) informatics tools to collect de-identified, person-level data across sites; and (3) a unified approach for analyzing pooled data and disseminating promising findings rapidly across the network. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-295.html (P01) https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-296.html (U24)	Up to \$1 million per year	Estimated post date: 11/27/23 Estimated proposal date: 3/15/24
		MUSCULOSKELETAL HEALTH (1)		
33.	Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional) (NIH) RFA-NS-23-032	This NOFO solicits applications for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research community. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-032.html	Up to \$1 million per year, for up to 4 years	Letter of intent: 10/28/23 Proposal: 11/28/23
		REGULATORY SCIENCE (1)		
34.	FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science (FDA) FDABAA-24-00123	This BAA supports research and development to support regulatory science and innovation. Research areas include: Modernize development and evaluation of FDA-regulated products; Strengthen post-market surveillance and labeling of FDA-regulated products; and Invigorate public health preparedness and response of the FDA, patients, and consumers. https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8314343cb/view	Dependent upon proposal and award mechanism	Early concept paper: 11/6/23 Concept paper and full proposal: 2/19/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT (6)		
35.	Chemical and Biological Defense SBIR 23.4 Phase I (DoD/DTRA) CBD234-P001	The open topic is Decontamination of Open Wounds: There is a clear need to develop an effective man-portable capability that will rapidly remove chemical warfare agents (CWAs) and other toxic industrial chemicals (TICs) of interest to the U.S. Department of Defense from human skin, both intact and wounded, under austere conditions. https://media.defense.gov/2023/Sep/28/2003309993/-1/1/o/CBD_SBIR_234_R1.PDF	Up to \$197,283, for up to 6 months (Phase I)	Proposal: 11/14/23
36.	NOAA SBIR FY 2024 Phase I (DoC/NOAA) NOAA-OAR-TPO-2024-2008184	The NOAA SBIR program seeks proposals for highly innovative products and services that have strong commercial potential and fit within the NOAA mission areas. Research topics are: Extreme Events and Cascading Hazards; Coastal Resilience; The Changing Ocean; Water Availability, Quality, and Risk; Effects of Space Weather; Monitoring and Modeling for Climate Change Mitigation https://www.grants.gov/web/grants/view-opportunity.html?oppld=350392	Up to \$175,000, for up to 6 months (Phase I) Up to \$650,000, for up to 2 years (Phase II)	Letter of intent: 11/22/23 Proposal: 12/20/23
37.	NOSI: Encouraging Small Businesses to Partner with Resource-Limited Institutions (RLIs) on SBIR and STTR Program Applications (NIH/OD) NOT-OD-23-179	NIH is interested in expanding the cadre of research institutions engaging in translation of their basic science discoveries to patient and economic benefit. NIH is also interested in enabling greater contribution to technology transfer and commercialization activities by scientists and trainees from populations underrepresented in the U.S. biomedical, behavioral, and social sciences research enterprise. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-179.html	Up to \$295,924 per year (Phase I) Up to \$1,972,828 per year, for up to 2 years (Phase II) Waiver topics may exceed these amounts	Multiple deadlines; NOSI open through 4/6/24
		SUBSTANCE USE DISORDER (7)		
38.	HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R01/R34 Clinical Trial Optional) (NIH) RFA-AA-23-005 (R01) RFA-AA-23-006 (R34)	These NOFOs support studies that will inform safe and effective medication-assisted, psychosocial, and complementary interventions for people with co-occurring Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD). Reciprocal relationships between opioid use and alcohol use has been observed for OUD-AUD patients such that reduced opioid intake may result in increased drinking which heightens opioid relapse and overdose risk and suggests an urgent need for targeted therapies in this population. https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-23-005.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-23-006.html (R34)	Up to \$250,000 per year, for up to 3 years	Letter of intent: 11/14/23 Proposal: 12/14/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
39.	Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional/BESH Required/R61/R33 Clinical Trial Optional) (NIH/NIDA) RFA-DA-24-031 (R01) RFA-DA-24-032 (R01) RFA-DA-24-033 (R61/R33)	The goal of these NOFOs is to identify novel targets for non-invasive brain stimulation (NIBS) and their influence on cortical networks and related cognitive constructs relevant to SUD treatment. Studies proposed should identify and validate new neuromodulation targets and provide a comprehensive understanding of the behavioral and neurobiological effects of stimulation to these targets and their constituent brain networks. The insight into the causal mechanisms of SUD provided by such NIBS studies would inform future clinical trial design via the identification of both new treatment-relevant stimulation targets and selection of proximal metrics of stimulation efficacy. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-031.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-032.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-033.html (R61/R33)	Dependent upon proposal, for up to 5 years (R01) Up to \$600,000, for up to 2 years (R66) Dependent upon proposal, for up to 3 years (R33)	Letter of intent: 12/16/23 Proposal: 1/16/24
40.	Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) (NIH/NIDA) RFA-DA-25-047 (R41/R42) RFA-DA-25-048 (R43/R44)	These NOFOs support applications from SBCs to develop technologies for commercialization to address health-related social needs that impact SUD, excluding AUD. Regarding this NOFO, a product can be a physical/tangible device as well as digital services, software as a service, or non-physical/non-tangible products. Products can be the result of original scientific research, recycled existing technology for SUD, extension of an observation into SUD area, development of a new business model or distribution/delivery channel that reveals currently unseen value, or the delivery of a product or service to disregarded consumers. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html (R41/R42) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-048.html (R43/R44)	Up to \$295,924 per year (Phase I) Up to \$1,972,828 per year, for up to 2 years (Phase II)	Letter of intent: 2/13/24 Proposal: 3/13/24
		TELEMEDICINE (1)		
41.	Pre-Announcement: Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) (NIH/NCCIH) NOT-AT-24-014	This NOFO encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully-powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-014.html	Up to \$500,000	Estimated post date: 12/4/23 Estimated proposal date: 2/5/24



Recurring Opportunities

October 4, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)		
42.	Open-Office Broad Agency Announcement (BAA) 75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems. https://sam.gov/opp/cafi09b75a0449418ead3630cef1915e/view	Dependent upon proposal and award mechanism	Abstract: 3/14/24
		AIR FORCE (3)		
43.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppld=327332	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26
44.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/web/grants/view-opportunity.html?oppld=345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE		
45.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
46.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
47.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
48.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; prolonged field care; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. Special Operations Forces medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
49.	Army Research Office Broad Agency Announcement for Fundamental Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here . https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
50.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
51.	Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppld=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
52.	Army Research Office Broad Agency Announcement Staff Research Program W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
53.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppld=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
54.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; COVID-19 Immune Assay(s) Development and Implementation; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/437e1da4c90345759330706d9391bebf/view	Dependent upon proposal	Proposal: 9/25/28



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA		
55.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	Deadlines vary by AOI" "BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #16: Lab at Home; AOI #17: Digital MCMs; AOI #19: Healing Lungs; AOI #22: ReBoot; AOI #24: REPAIR; AOI #25: FASTx; AOI #26: Agnostic Diagnostic. https://sam.gov/opp/79482f9236c64929938197ae21e9347a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
56.	Biological Technologies BAA HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24
57.	Defense Sciences Office, Office-wide HR001123S0053	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/972be70efd7e4608b01311466edf6b0f/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24
		DEFENSE THREAT REDUCTION AGENCY (2)		
58.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
59.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
60.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppld=350408	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24
		NATIONAL SCIENCE FOUNDATION (1)		
61.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the project pitch details and the full list of topics . https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/6/23 to 11/1/23
		NAVY (3)		
62.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
63.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY		
64.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/ee708f6d2e244d0bb59d582c0362d9d1/view	Dependent upon proposal and award mechanism	White papers accepted through 12/29/23





Terms

AD/ADDR: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aol: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

[Back to Table of Contents](#)

GBG Acronyms

Updated Monthly

October 4, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine

